Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Cleary, Brian JDonnelly, Jean M
Strawbridge, Judith D
Gallagher, Paul J
Fahey, Tom
White, Martin J
Murphy, Deirdre J
Affiliation
Department of Obstetrics and Gynecology, Trinity College Dublin, Royal College of, Surgeons in Ireland, Dublin, Republic of Ireland. bcleary@coombe.ieIssue Date
2012-02-01T10:57:19ZMeSH
Age FactorsDose-Response Relationship, Drug
Female
Humans
Infant, Newborn
Methadone/*adverse effects/therapeutic use
Narcotics/adverse effects/therapeutic use
Neonatal Abstinence Syndrome/diagnosis/*etiology
Odds Ratio
*Opiate Substitution Treatment
Opioid-Related Disorders/*rehabilitation
Pregnancy
Premature Birth/*etiology
Retrospective Studies
Risk Factors
Smoking
Treatment Outcome
Metadata
Show full item recordCitation
Am J Obstet Gynecol. 2011 Feb;204(2):139.e1-9. Epub 2010 Dec 8.Journal
American journal of obstetrics and gynecologyDOI
10.1016/j.ajog.2010.10.004PubMed ID
21145035Abstract
OBJECTIVE: The purpose of this study was to examine the relationship among methadone maintenance treatment, perinatal outcomes, and neonatal abstinence syndrome. STUDY DESIGN: This was a retrospective cohort study of 61,030 singleton births at a large maternity hospital from 2000-2007. RESULTS: There were 618 (1%) women on methadone at delivery. Methadone-exposed women were more likely to be younger, to book late for antenatal care, and to be smokers. Methadone exposure was associated with an increased risk of very preterm birth <32 weeks of gestation (adjusted odds ratio [aOR], 2.47; 95% confidence interval [CI], 1.40-4.34), being small for gestational age <10th percentile (aOR, 3.27; 95% CI, 2.49-4.28), admission to the neonatal unit (aOR, 9.14; 95% CI, 7.21-11.57), and diagnosis of a major congenital anomaly (aOR, 1.94; 95% CI, 1.10-3.43). There was a dose-response relationship between methadone and neonatal abstinence syndrome. CONCLUSION: Methadone exposure is associated with an increased risk of adverse perinatal outcomes, even when known adverse sociodemographic factors have been accounted for. Methadone dose at delivery is 1 of the determinants of neonatal abstinence syndrome.Language
engISSN
1097-6868 (Electronic)0002-9378 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1016/j.ajog.2010.10.004
Scopus Count
Collections
Related articles
- Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.
- Authors: Wang S, Meador KJ, Pawasauskas J, Lewkowitz AK, Ward KE, Brothers TN, Hartzema A, Quilliam BJ, Wen X
- Issue date: 2023 Mar
- Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
- Authors: Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J
- Issue date: 2011 Apr
- Methadone and perinatal outcomes: a prospective cohort study.
- Authors: Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, White MJ, McDermott C, O'Sullivan A, Carmody D, Gleeson J, Murphy DJ
- Issue date: 2012 Aug
- Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome.
- Authors: Tolia VN, Murthy K, Bennett MM, Miller ES, Benjamin DK, Smith PB, Clark RH
- Issue date: 2018 Jan
- Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources.
- Authors: Dryden C, Young D, Hepburn M, Mactier H
- Issue date: 2009 Apr